These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 26183118)
1. The art of modeling adherence: shades or shapes? Parienti JJ Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1114-6. PubMed ID: 26183118 [No Abstract] [Full Text] [Related]
2. Computerized community cholesterol control (4C): meeting the challenge of secondary prevention. Gilutz H; Novack L; Shvartzman P; Zelingher J; Bonneh DY; Henkin Y; Maislos M; Peleg R; Liss Z; Rabinowitz G; Vardy D; Zahger D; Ilia R; Leibermann N; Porath A Isr Med Assoc J; 2009 Jan; 11(1):23-9. PubMed ID: 19344008 [TBL] [Abstract][Full Text] [Related]
3. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Naderi SH; Bestwick JP; Wald DS Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400 [TBL] [Abstract][Full Text] [Related]
4. Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Celik M; Celik T Anadolu Kardiyol Derg; 2009 Jun; 9(3):253; author reply 253-4. PubMed ID: 19520663 [No Abstract] [Full Text] [Related]
5. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study. Ivers NM; Schwalm JD; Jackevicius CA; Guo H; Tu JV; Natarajan M Can J Cardiol; 2013 Nov; 29(11):1408-14. PubMed ID: 23816280 [TBL] [Abstract][Full Text] [Related]
6. Statins and myocardial infarction: Type, dose, and administration time: Does it matter? Papageorgiou N; Zacharia E; Briasoulis A; Androulakis E; Tousoulis D Trends Cardiovasc Med; 2016 Jul; 26(5):433-41. PubMed ID: 26948202 [TBL] [Abstract][Full Text] [Related]
7. Side effects don't have to stop statin users. Harv Womens Health Watch; 2013 Jul; 20(11):8. PubMed ID: 24818281 [No Abstract] [Full Text] [Related]
8. Evaluation of the impact of the recent controversy over statins in France: the EVANS study. Saib A; Sabbah L; Perdrix L; Blanchard D; Danchin N; Puymirat E Arch Cardiovasc Dis; 2013 Oct; 106(10):511-6. PubMed ID: 24080324 [TBL] [Abstract][Full Text] [Related]
9. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Maddox TM; Ho PM Curr Opin Cardiol; 2009 Sep; 24(5):468-72. PubMed ID: 19550308 [TBL] [Abstract][Full Text] [Related]
10. Primary prevention. Smith ER Can J Cardiol; 2004 Nov; 20(13):1373-4. PubMed ID: 15565204 [No Abstract] [Full Text] [Related]
12. Statins: established indications and controversial subgroups. Goldstein MR; Mascitelli L; Pezzetta F Heart; 2009 May; 95(10):846-7. PubMed ID: 19401284 [No Abstract] [Full Text] [Related]
13. Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application. Slejko JF; Sullivan PW; Anderson HD; Ho PM; Nair KV; Campbell JD Value Health; 2014 Sep; 17(6):725-31. PubMed ID: 25236996 [TBL] [Abstract][Full Text] [Related]
14. Primary risk prevention in the elderly: use clinician-patient discussions, not automatic statin prescribing. Stone NJ; Blum CB Am J Med; 2015 Aug; 128(8):804-6. PubMed ID: 25820167 [No Abstract] [Full Text] [Related]
15. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL; Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583 [TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679 [TBL] [Abstract][Full Text] [Related]
17. Coronary artery disease prevention: as easy as 1, 2, 3? Lucan SC Am Fam Physician; 2010 Nov; 82(10):1167. PubMed ID: 21121526 [No Abstract] [Full Text] [Related]
18. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1). Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366 [TBL] [Abstract][Full Text] [Related]
19. [Statins with a perspective of lifelong therapy]. Ertaş FS Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048 [TBL] [Abstract][Full Text] [Related]
20. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys. Pajak A; Jankowski P; Kawecka-Jaszcz K; Surowiec S; Wolfshaut R; Loster M; Batko K; Badacz L; Dubiel JS; Grodecki J; Grodzicki T; Maciejewicz J; Mirek-Bryniarska E; Piotrowski W; Smielak-Korombel W; Tracz W Kardiol Pol; 2009 Dec; 67(12):1353-9. PubMed ID: 20054766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]